A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
HOME > COMMENTARY
COMMENTARY
-
Can Japan Craft Its Own “Compassionate Use” System without Spoiling Drug Makers’ Development Drives?
December 7, 2012
-
Recent Announcements of Suspended Product Supplies Highlight Supply Risks Faced by Generic Drug Industry
November 27, 2012
-
Will Integration of Domestic Makers Be Enough for Sustainable Plasma Fractionation Operations?
November 16, 2012
-
Approval of Switch-OTC Epadel Puts Spotlight on Quality, Track Record of Pharmacists
November 9, 2012
-
Final Preparations Underway for Trial Run of Medical Database
September 25, 2012
-
Competition Getting Fiercer in COPD Drug Market
September 13, 2012
-
FY2013 Budget Expected to Have Positive Impact on Pharmaceutical and Medical Device Industries
August 30, 2012
-
Pharmaceutical Bar Coding Initiatives Spreading Among Western Countries
August 21, 2012
-
Government Shows Consideration towards Municipalities on IPV Price Issue
August 14, 2012
-
Challenges Emerging from Hiroshima: Improvement of Wholesalers' “Services of Convenience”
August 1, 2012
-
Integration of Advanced Healthcare System to Strengthen Linkage Between Development, Insurance, and Regulatory Approval
July 10, 2012
-
Major Generic Drug Makers Trying New Strategies to Boost Product Strengths
July 6, 2012
-
Gov’t to Support Development of Innovative Drugs of Japanese Origin through Drug Discovery Support Network
June 22, 2012
-
Discussions on Long-Listed Drugs Must Balance Interests of All Stakeholders
June 14, 2012
-
Supply of New Drugs Prior to NHI Price Listing to Increase as More Makers Target Drugs with Unmet Medical Needs
April 20, 2012
-
Fewer Takers, High Pass Rate in Nat’l Pharmacists’ Exam for 1st Graduates of Six-year Education System
April 5, 2012
-
Recent Topics in Hopeful Drugs and Candidates with Unique Mode of Action: 2
March 26, 2012
-
Recent Topics in Hopeful Drugs and Candidates with Unique Mode of Action: 1
March 19, 2012
-
Indications for Boosted Alliances, Acquisitions in Vaccine Business among Major Japanese Companies
March 13, 2012
-
Further Provisions Required – One Year since the Great East Japan Earthquake
March 12, 2012
ページ
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…